This new addition is a clear commitment to innovation and minimally invasive treatments. With the backing of Fremman Capital, Palex Medical continues with its growth and diversification plan, previously supported by Ergon Capital and Corpfin Capital, since 2016.
The Palex Group has recently acquired Wacrees, a company founded in 1991 and dedicated to finding the best solutions for interventional radiology and vascular processes, in collaboration with world-class partners. With this new addition, Palex expands its offer in vascular patient care, strengthens its growth and diversification plan initiated in 2016, and reinforces its commitment to innovation and minimally invasive treatments.
The incorporation of Wacrees, in addition to the recent acquisitions of Comercial Rafer and the proton therapy branch of Bioterra, will increase the number of specialities to which Palex offers solutions and reinforce its leadership in the Spanish market.
Wacrees’ high level of commitment to its customers translates into long-term commercial agreements with its international partners.
Palex and Wacrees share the goal of offering maximum innovation to the different medical specialities and this acquisition reinforces Palex’s commitment to offering minimally invasive solutions and treatments.
Xavier Carbonell, CEO of the Palex group, highlights: “With the addition of Wacrees and our extensive knowledge of the market, both in Spain and Portugal, we will have access to new innovative solutions that will reinforce our leadership in the sector and expand our ability to successfully meet the challenges demanded by healthcare professionals and the quality of life of patients.”
RocaJunyent’s team advising Palex Medical was led by partner Alex Llevat Felius and associate Laura García Wintzer.
